AKT1 and cancer: By downregulating ERK1/2 and Akt phosphorylation, the combination therapy of axitinib and irinotecan showed antiproliferative and proapoptotic activity and significantly inhibited the expression of the ATP7A and ABCG2 genes in endothelial and cancer cells [81].